Second, activation of the Wnt pathway by AR79, a glycogen synthase kinase 3 (GSK-3) inhibitor, can increase the proportion of ALDH+CD133+ stem-like prostate cancer cells (Jiang et al., 2013). The gene discussed is PROM1; the disease is prostate carcinoma.